CRITICAL PATH INSTITUTE

Watch now: Shortening the Timeline for Developing New Treatments – How the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) Can Help Webinar

Join C-Path, the National Organization for Rare Disorders and the FDA for a free 1-hour webinar on the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), an integrated database and analytics hub designed to be used in building novel tools to accelerate drug development across rare diseases.

Wednesday, June 24
2:00 – 3:00pm EDT

Watch Now

Webinar: Shortening the Timeline for Developing New Treatments – How the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) Can Help

Join the National Organization for Rare Disorders (NORD®), Critical Path Institute (C-Path), and the US Food and Drug Administration (FDA) for an exclusive webinar on the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). RDCA-DAP is an integrated database and analytics hub designed to build novel tools to accelerate drug development across rare diseases.

This webinar will explore why your organization should contribute to the RDCA-DAP, how to submit data, and how you can access and use the data and analytics platform. NORD, C-Path, and FDA will be available to answer specific questions about the project.

This webinar is appropriate for pharmaceutical, biotech, and medical device companies working in rare disease research and drug development, though all are welcome to join. Content will be of greatest interest to Chief Medical Officers, Heads of Clinical Development, Directors of Data Analytics, R&D, Data Science, Corporate Compliance, Corporate Affairs, and Advocacy.

Webinar Speakers:

Pamela Gavin, Chief Strategy Officer, National Organization for Rare Disorders

Michelle Campbell, PhD, Sr. Clinical Analyst Stakeholder Engagement and Clinical Outcomes, FDA, Center for Drug Evaluation and Research

Jane Larkindale, DPhil, Executive Director, Rare Disease Cures Accelerator-Data and Analytics Platform and Duchenne Regulatory Science Consortium, Critical Path Institute

Robert C. Alexander, MD, Vice President and Head, Global Clinical Science Neuroscience Therapeutic Area Unit, Takeda Pharmaceuticals International Co.

Funding for this webinar was made possible, in part, by the US Food and Drug Administration through grant U18 FD 005320. Views expressed in written materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.